0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
 
   Acacia Pharma Group plc: Notice of Annual General Meeting 
 
   Cambridge, UK and Indianapolis, US -- 25 May 2021 Acacia Pharma Group 
plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH), a hospital 
pharmaceutical company focused on the development and commercialization 
of new products aimed at improving the care of patients undergoing 
significant treatments such as surgery, other invasive procedures or 
cancer chemotherapy, announces that its annual general meeting of 
shareholders ("AGM") will be held at 2:00pm BST on Monday 28 June 2021 
at the offices of Acacia Pharma Inc, 8440 Allison Pointe Boulevard, 
Suite 100, Indianapolis, IN 46250, United States. 
 
   The formal notice convening the AGM (including agenda, information on 
attending the meeting in person or by proxy, requirements for 
notification and registration for the meeting) together with the Form of 
Proxy, and the Company's Annual Report and Accounts for the year ended 
31 December 2020, will be posted to shareholders today and are available 
from today on the Company's website www.acaciapharma.com in the 
Investors/Shareholder Meetings section and the Investors/Financial 
Reports section, respectively. 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
available in the US for the management of postoperative nausea & 
vomiting (PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centred in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   www.acaciapharma.com 
 
 
 
 

(END) Dow Jones Newswires

May 25, 2021 12:00 ET (16:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024